High-Fat Diet (HFD) & Streptozotocin (STZ) induced Type II Diabetes (T2D) Modeling & Pharmacodynamics Service
Creative Biolabs offers a range of advanced and reliable animal models, including the High-Fat Diet & Streptozotocin (STZ)-Induced Type II Diabetes Model, to help evaluate the efficacy of therapeutic agents. Our models are designed to provide an accurate representation of the disease, supporting your research in finding effective treatments for Type II Diabetes.
Introduction
Type II Diabetes (T2D) is a chronic metabolic disorder characterized by insulin resistance and impaired insulin secretion, leading to elevated blood glucose levels. Unlike Type I Diabetes, where the body's immune system destroys insulin-producing β-cells, Type II Diabetes results from the body's inability to respond effectively to insulin, a condition called insulin resistance. Over time, the pancreas produces more insulin to compensate, but eventually, the β-cells become exhausted, and blood glucose levels rise. T2D is closely associated with obesity, poor diet, and sedentary lifestyle, making it a significant public health challenge worldwide. Complications arising from T2D include cardiovascular diseases, neuropathy, kidney failure, and vision problems. Early diagnosis and intervention can mitigate these risks.
Disease Models and Applications
The High-Fat Diet & Streptozotocin (STZ)-Induced Type II Diabetes Model is one of the most used approaches for studying Type II Diabetes in rodents. This model involves feeding rats a high-fat diet to induce obesity, followed by the administration of low-dose Streptozotocin (STZ), a chemical that induces pancreatic β-cell dysfunction and insulin resistance. The combination of these two factors leads to elevated blood glucose levels, mimicking the pathophysiology of human Type II Diabetes. This model is particularly useful for studying obesity-induced diabetes and evaluating the efficacy of anti-diabetic drugs targeting insulin resistance and β-cell preservation. One of the advantages of this model is its ability to simulate both obesity and diabetes, making it a comprehensive tool for research. However, the model has limitations, such as the variability in diabetes onset and the lack of complete replication of the complexity of human diabetes, particularly in terms of long-term complications.
- Simulates: The High-Fat Diet & Streptozotocin (STZ)-Induced Type II Diabetes Model simulates the development of insulin resistance and hyperglycemia, key features of human Type II Diabetes. The combination of high-fat diet-induced obesity and STZ-induced β-cell dysfunction closely mimics the disease progression in humans.
- Evaluates Drugs: This model is widely used to evaluate the efficacy of drugs aimed at improving insulin sensitivity, controlling blood glucose levels, and preventing β-cell degeneration. It is ideal for testing therapies that target metabolic dysfunction, inflammation, and obesity-related complications, providing valuable insights into drug efficacy.
Measurements
We offer a variety of measurements for evaluating drug efficacy in the High-Fat Diet & Streptozotocin (STZ)-Induced Type II Diabetes Model, utilizing advanced technologies, including but not limited to:
- General observations: body weight, blood glucose levels, food and water intake, activity levels.
- Glucose tolerance test (GTT): Assessment of insulin sensitivity and glucose metabolism.
- Hematology analysis: Measurement of blood parameters such as red blood cell count, white blood cell count, and platelets.
- Serum biomarkers: Levels of insulin, HbA1c, and other metabolic markers.
- Histopathology: Examination of pancreatic, liver, and kidney tissues for signs of diabetic complications such as β-cell loss, steatosis, and nephropathy.
- Gene/protein expression profiling: Quantification of key molecules involved in glucose metabolism and insulin signaling via RT-qPCR and Western blot.
Our team is available to assist with experimental design, model selection, and data analysis, ensuring a tailored approach for your research needs.
Related Services
In addition to the High-Fat Diet & Streptozotocin (STZ)-Induced Type II Diabetes Model, we also offer other models for studying Type II Diabetes, such as the Zucker Diabetic Fatty (ZDF) model and the Genetic Type II Diabetes Rat Model. These models allow for the exploration of different mechanisms underlying diabetes and its complications.
- Non-Obese Type I Diabetes Mouse Model
- Streptozotocin (STZ) induced Type I Diabetes Model
- Alloxan induced Type I Diabetes Model
- db/db Type II Diabetes Mouse Model
- Intrauterine Growth Retardation (IUGR)-Diabetic Model
- STZ-NA induced Type II Diabetes Rat Model
- Zucker Diabetic Fatty (ZDF) Type II Diabetes Rat Model
- Combined Spleen & Partial Pancreas Resection & Glucocorticoid induced Type II Diabetes Model
Advantages
- Expertise in Diabetes Models: We specialize in providing reliable and reproducible models for Type II Diabetes research, ensuring accurate data for drug testing and development.
- Comprehensive Solutions: We offer a wide variety of models tailored to different research needs, including models for obesity, insulin resistance, and diabetes-related complications.
- Advanced Technologies: Our cutting-edge tools for data collection, including glucose metabolism analysis, histopathology, and gene expression profiling, ensure the highest quality results.
- Customizable Research: We provide flexible experimental designs, allowing you to tailor the research to your specific needs, whether for drug efficacy or mechanistic studies.
- Expert Support: Our team of scientists offers full support throughout your project, from model selection to data analysis, helping ensure the success of your research.
- Global Reach: We support researchers worldwide, providing high-quality services with a focus on meeting international standards.
Work with Us
- Summarize the project requirements and fill in the information collection form.
- Sign a CDA from both parties to further communicate information, such as targets.
- Select an animal model, discuss experimental design, and determine assay parameters.
- Project costing and project schedule forecasting.
- We provide a detailed project plan, including the required sample quantities, methods, and protocols.
- Both parties confirm the project details and start the project.
- Confirm the timeline of the project.
- We provide periodic results and information on the animal's condition.
- We will work together to make project adjustments as necessary.
- We provide a comprehensive project report promptly.
- We arrange transportation for the produced samples.
- We provide a discussion of the project results and help to arrange the next steps.
- Data storage and archiving.
FAQs
-
Q: What is the primary advantage of using the High-Fat Diet & STZ-Induced Type II Diabetes Model?
A: This model closely mimics the development of insulin resistance and hyperglycemia, making it ideal for studying the metabolic dysfunctions associated with Type II Diabetes.
-
Q: How long does it take for Type II Diabetes to develop in this model?
A: Diabetes typically develops within 6-8 weeks after the administration of a high-fat diet and STZ, depending on the specific protocols used.
-
Q: Can this model be used to study diabetic complications like kidney disease?
A: Yes, the model can be used to evaluate kidney damage and other complications associated with Type II Diabetes, providing a comprehensive platform for studying comorbidities.
-
Q: Do you offer any services for data analysis or experimental design?
A: Yes, our experienced scientific team is available to assist in experimental design, model selection, and data analysis to ensure the success and accuracy of your research.
Published Data
Fig. 1 HFD (high-fat and high-glucose diet) combined with STZ (streptozotocin) induces type 2 diabetes model in mice.1
The aim of this study was to investigate the effect of CVB-D on cardiomyocyte pyroptosis in the context of diabetic cardiomyopathy (DCM) and its underlying molecular mechanisms. Type 2 diabetes was induced in mice through a high-fat diet (HFD) combined with intraperitoneal injections of streptozotocin (STZ). As shown in **Figure 1A**, the model mice developed significant insulin resistance after 12 weeks of HFD compared to the control group. The intraperitoneal glucose tolerance test (IPGTT) results demonstrated that blood glucose levels in the HFD group were significantly elevated at 0, 15, 30, 60, 90, and 120 minutes post-glucose injection (Figure 1B), with the area under the curve (AUC) of blood glucose being larger in the HFD group than in the control group (Figure 1C). Additionally, serum levels of fasting blood glucose (FBG), cholesterol (CHO), and triglycerides (TG) were significantly higher in the model group compared to the control group. However, CVB-D did not improve these metabolic parameters, indicating that CVB-D did not ameliorate the metabolic disorders associated with Type 2 diabetes in mice (Figures 1D–F).
Reference
- Gao, Ge et al. "Cyclovirobuxine D Ameliorates Experimental Diabetic Cardiomyopathy by Inhibiting Cardiomyocyte Pyroptosis via NLRP3 in vivo and in vitro." Frontiers in Pharmacology vol. 13 906548. 5 Jul. 2022, DOI:10.3389/fphar.2022.906548. Distributed under an Open Access license CC BY 4.0, without modification.
For Research Use Only.